安罗替尼治疗非小细胞肺癌的近期疗效及对血清肿瘤标志物 CTC VGEF水平和毒副作用的影响

doi:10.3969/j.issn.1006-6233.2021.11.029

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1208 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the short-term efficacy of anlotinib in the treatment of non-small cell lung cancer (NSCLC), and its influence on serum tumor markers, circulating tumor cells (CTC), vascular endothelial growth factor (VGEF) and side effects. Methods: Totally 94 patients with NSCLC treated in the hospital were selected between August 2019 and December 2020. They were divided into anlotinib group (n=49, anlotinib) and control group (n=45, conventional chemotherapy) according to random number table method. Relevant parameters were compared between the two groups. Results: The total response rate and Karnofsky Performance Scale (KPS) score of the observation group were higher than those of the control group (P<0.001). After treatment, there was no difference in the positive detection rate of CTC between the two groups (P>0.05), but the concentrations of VGEF, serum tumor markers carcino-embryonic antigen (CEA) and cytokeratin 19 fragment antigen 21-1 in the anlotinib group were lower than those in the control group (P<0.05). There were no differences in the total incidence and severity of adverse reactions between the two groups (P>0.05). Hypertension, thyroid dysfunction, and hand-foot syndrome were main adverse reactions in the anlotinib group, which were controlled after reduction and symptomatic treatment. Conclusion: Anlotinib can significantly improve the short-term efficacy in the treatment of NSCLC, effectively lower the levels of serum tumor markers and VGEF as well as the positive detection rate of CTC, and improve the patients’ quality of life. Therefore, it is worthy of clinical promotion and application.

Key words： Anlotinib Non-small cell lung cancer Short-term efficacy Serum tumor marker Side effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.11.029 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I11/1908

[1] Ahn B C,Pyo K H,Xin C F,et al.Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice[J].Cancer Res Clin Oncol,2019,145(6):1613~1623.
[2] 任晓辉,张霞,于剑飞,等.表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的效果及对免疫功能的调节作用[J].中国临床实用医学,2021,12(1):12~17.
[3] 闻艺璇,梁利军,陈婷,等.安罗替尼临床应用研究进展[J].中华肿瘤防治杂志,2019,26(14):979~985.
[4] 靳宏虎,赵长应,张桢,等.两种实体瘤疗效评价标准对肝细胞癌患者系统化疗效果评价的比较[J].中华肝胆外科杂志,2019,25(6):411~414.
[5] 闫美玲,张萌,黄琳,等.BCR-ABL^35INS突变型慢性粒细胞白血病患者选用酪氨酸激酶抑制剂的文献分析[J].中国药房,2019,30(12):1675~1678.
[6] 陈恩立,张宏涛,刘泽洲,等.CT引导125I粒子植入治疗头颈部复发转移肿瘤近期疗效的影响因素分析[J].中华核医学与分子影像杂志,2020,40(2):93~97.
[7] 韦婷婷,蓝柳,赵迎喜,等.安罗替尼在晚期非小细胞肺癌真实世界非一线治疗中的临床效果[J].广西医学,2021,43(6):664~669.
[8] Hsu P,Chang J W,Wang C,et al.Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III nonmall cell lung cancer:Results of a singlerm prospective cohort study[J].Thoracic Cancer,2019,10(8):1683~1691.
[9] 刘楠,吴秀伟,李烦繁,等.安罗替尼三线及以上治疗晚期非小细胞肺癌近期疗效和生命质量分析[J].国际肿瘤学杂志,2019,46(3):147~152.
[10] 夏波,程志祥.盐酸安罗替尼治疗晚期非小细胞肺癌的研究进展[J].中国医药导报,2020,17(30):59~61,69.
[11] 左扬松,濮娟,沈文沂,等.培美曲塞二钠治疗晚期非小细胞肺癌的效果及毒副作用[J].中国临床保健杂志,2019,22(4):496~499.